STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model
Abstract
:1. Introduction
2. Materials and Methods
2.1. Preparation of Primary Cell Lines
2.2. Cell Lines
2.3. Reagents and Antibodies
2.4. Western Blot Analysis
2.5. RNA Extraction and Quantitative Real-Time PCR
2.6. Cell Viability Assay
2.7. Immunofluorescence Staining
2.8. Tissue Staining and Immunohistochemistry
2.9. Flow Cytometry
2.10. Wound Healing and Invasion Assays
2.11. In vitro Limiting Dilution and Sphere-Forming Assays
2.12. In vivo xenograft models
2.13. Statistics
3. Results
3.1. STAT3 Hyperactivation Increases Tumor Malignancy and Decreases Survival in Glioblastoma Patients
3.2. ODZ10117 Inhibits STAT3 Activation in Glioblastoma Cells
3.3. ODZ10117 Reduces the Migration and Invasion of Glioblastoma Cells
3.4. ODZ10117 Decreases the Viability of Glioblastoma Cells by Inducing Apoptosis
3.5. ODZ10117 Decreases Stem Cell Properties by Inhibiting STAT3 in Glioblastoma Stem Cells
3.6. ODZ10117 Reduces Tumor Growth in Glioblastoma Xenografts
4. Discussion
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
CSC | cancer stem cell |
DAPI | 4′,6-diamidino-2-phenylindole |
FITC | fluorescein isothiocyanate |
GSC | glioma stem cell |
H&E | hematoxylin and eosin |
IL-6 | interleukin 6 |
JAK | Janus kinase |
PE | phycoerythrin |
PI | propidium iodide |
qPCR | quantitative real-time polymerase chain reaction |
STAT3 | signal transducer and activator of transcription 3 |
TCGA | The Cancer Genomic Atlas |
WHO | World Health Organization |
References
- Davis, M.E. Glioblastoma: Overview of Disease and Treatment. Clin. J. Oncol. Nurs. 2016, 20, S2–S8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shergalis, A.; Bankhead, A., 3rd; Luesakul, U.; Muangsin, N.; Neamati, N. Current Challenges and Opportunities in Treating Glioblastoma. Pharmacol. Rev. 2018, 70, 412–445. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Spitzner, M.; Ebner, R.; Wolff, H.A.; Ghadimi, B.M.; Wienands, J.; Grade, M. STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy. Cancers (Basel) 2014, 6, 1986–2011. [Google Scholar] [CrossRef] [PubMed]
- Tan, M.S.Y.; Sandanaraj, E.; Chong, Y.K.; Lim, S.W.; Koh, L.W.H.; Ng, W.H.; Tan, N.S.; Tan, P.; Ang, B.T.; Tang, C. A STAT3-based gene signature stratifies glioma patients for targeted therapy. Nat. Commun. 2019, 10, 3601. [Google Scholar] [CrossRef]
- Kim, B.H.; Yi, E.H.; Ye, S.K. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment. Arch. Pharm. Res. 2016, 39, 1085–1099. [Google Scholar] [CrossRef]
- Lee, H.; Jeong, A.J.; Ye, S.K. Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep. 2019, 52, 415–423. [Google Scholar] [CrossRef] [Green Version]
- Diaz, N.; Minton, S.; Cox, C.; Bowman, T.; Gritsko, T.; Garcia, R.; Eweis, I.; Wloch, M.; Livingston, S.; Seijo, E.; et al. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and surviving expression. Clin. Cancer Res. 2006, 12, 20–28. [Google Scholar] [CrossRef] [Green Version]
- Won, C.; Kim, B.H.; Yi, E.H.; Choi, K.J.; Kim, E.K.; Jeong, J.M.; Lee, J.H.; Jang, J.J.; Yoon, J.H.; Jeong, W.I.; et al. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology 2015, 62, 1160–1173. [Google Scholar] [CrossRef] [Green Version]
- Arora, L.; Kumar, A.P.; Arfuso, F.; Chng, W.J.; Sethi, G. The Role of Signal Transducer and Activator of Transcription (STAT3) and Its Targeted Inhibition in Hematological Malignancies. Cancers (Basel) 2018, 10, E327. [Google Scholar] [CrossRef] [Green Version]
- Igelmann, S.; Neubauer, H.A.; Ferbeyre, G. STAT3 and STAT5 Activation in Solid Cancers. Cancers (Basel) 2019, 11, E1428. [Google Scholar] [CrossRef] [Green Version]
- Piperi, C.; Papavassiliou, K.A.; Papavassiliou, A.G. Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment. Cells 2019, 8, E1398. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Furtek, S.L.; Backos, D.S.; Matheson, C.J.; Reigan, P. Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem. Biol. 2016, 11, 308–318. [Google Scholar] [CrossRef] [PubMed]
- Qin, J.J.; Yan, L.; Zhang, J.; Zhang, W.D. STAT3 as a potential therapeutic target in triple negative breast cancer: A systematic review. J. Exp. Clin. Cancer Res. 2019, 38, 195. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Lv, J.; Yang, W.; Xu, B.; Wang, Z.; Yu, Z.; Wu, J.; Yang, Y.; Han, Y. Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis. Theranostics 2019, 9, 6424–6442. [Google Scholar] [CrossRef] [PubMed]
- Kim, B.H.; Lee, H.; Song, Y.; Park, J.S.; Gadhe, C.G.; Choi, J.; Lee, C.G.; Pae, A.N.; Kim, S.; Ye, S.K. Development of Oxadiazole-Based ODZ10117 as a Small-Molecule Inhibitor of STAT3 for Targeted Cancer Therapy. J. Clin. Med. 2019, 8, E1847. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siddiquee, K.; Zhang, S.; Guida, W.C.; Blaskovich, M.A.; Greedy, B.; Lawrence, H.R.; Yip, M.L.; Jove, R.; McLaughlin, M.M.; Lawrence, N.J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. USA 2007, 104, 7391–7396. [Google Scholar] [CrossRef] [Green Version]
- Song, H.; Wang, R.; Wang, S.; Lin, J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA 2005, 102, 4700–4705. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nelson, E.A.; Walker, S.R.; Kepich, A.; Gashin, L.B.; Hideshima, T.; Ikeda, H.; Chauhan, D.; Anderson, K.C.; Frank, D.A. Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 2008, 112, 5095–5102. [Google Scholar] [CrossRef] [Green Version]
- Kim, B.H.; Jee, J.G.; Yin, C.H.; Sandoval, C.; Jayabose, S.; Kitamura, D.; Bach, E.A.; Baeg, G.H. NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3. Mol. Cancer 2010, 9, 36. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Rogoff, H.A.; Keates, S.; Gao, Y.; Murikipudi, S.; Mikule, K.; Leggett, D.; Li, W.; Pardee, A.B.; Li, C.J. Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc. Natl. Acad. Sci. USA 2015, 112, 1839–1844. [Google Scholar] [CrossRef] [Green Version]
- Hu, Y.; Smyth, G.K. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 2009, 347, 70–78. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.E.; Patel, M.; Ruzevick, J.; Jackson, C.M.; Lim, M. STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications. Cancers (Basel) 2014, 6, 376–395. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Clark, A.G.; Vignjevic, D.M. Modes of cancer cell invasion and the role of the microenvironment. Curr. Opin. Cell Biol. 2015, 36, 13–22. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, H.; Lee, H.; Herrmann, A.; Buettner, R.; Jove, R. Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat. Rev. Cancer. 2014, 14, 736–746. [Google Scholar] [CrossRef] [PubMed]
- Jin, W. Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition. Cells 2020, 9, E217. [Google Scholar] [CrossRef] [Green Version]
- Cancer Genome Atlas Research Network. Comprehensive genome characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061–1068. [Google Scholar] [CrossRef]
- Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17, 98–110. [Google Scholar] [CrossRef] [Green Version]
- Mao, P.; Joshi, K.; Li, J.; Kim, S.H.; Li, P.; Santana-Santos, L.; Luthra, S.; Chandran, U.R.; Benos, P.V.; Smith, L.; et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl. Acad. Sci. USA 2013, 110, 8644–8649. [Google Scholar] [CrossRef] [Green Version]
- Rogers, T.W.; Toor, G.; Drummond, K.; Love, C.; Field, K.; Asher, R.; Tsui, A.; Buckland, M.; Gonzales, M. The 2016 revision of the WHO Classification of Central Nervous System Tumours: Retrospective application to a cohort of diffuse gliomas. J. Neurooncol. 2018, 137, 181–189. [Google Scholar] [CrossRef]
- Hambardzumyan, D.; Bergers, G. Glioblastoma: Defining Tumor Niches. Trends Cancer 2015, 1, 252–265. [Google Scholar] [CrossRef]
- Lin, G.S.; Yang, L.J.; Wang, X.F.; Chen, Y.P.; Tang, W.L.; Chen, L.; Lin, Z.X. STAT3 Tyr705 phosphorylation affects clinical outcome in patients with newly diagnosed supratentorial glioblastoma. Med. Oncol. 2014, 31, 924. [Google Scholar] [CrossRef] [PubMed]
- Lobo, N.A.; Shimono, Y.; Qian, D.; Clarke, M.F. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 2007, 23, 675–699. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Medema, J.P. Cancer stem cells: The challenges ahead. Nat. Cell Biol. 2013, 15, 338–344. [Google Scholar] [CrossRef] [PubMed]
- Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature 2004, 432, 396–401. [Google Scholar] [CrossRef] [PubMed]
- Tamase, A.; Muraguchi, T.; Naka, K.; Tanaka, S.; Kinoshita, M.; Hoshii, T.; Ohmura, M.; Shugo, H.; Ooshio, T.; Nakada, M.; et al. Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc. Natl. Acad. Sci. USA 2009, 106, 17163–17168. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Deleyrolle, L.P.; Harding, A.; Cato, K.; Siebzehnrubl, F.A.; Rahman, M.; Azari, H.; Olson, S.; Gabrielli, B.; Osborne, G.; Vescovi, A.; et al. Evidence for label-retaining tumour-initiation cells in human glioblastoma. Brain 2011, 134, 1331–1343. [Google Scholar] [CrossRef]
- Cusulin, C.; Chesnelong, C.; Bose, P.; Bilenky, M.; Kopciuk, K.; Chan, J.A.; Cairncross, J.G.; Jones, S.J.; Marra, M.A.; Luchman, H.A.; et al. Precursor States of Brain Tumor Initiation Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes. Stem Cell Rep. 2015, 5, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Hossain, A.; Gumin, J.; Gao, F.; Figueroa, J.; Shinojima, N.; Takezaki, T.; Priebe, W.; Villarreal, D.; Kang, S.G.; Joyce, C.; et al. Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintains Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells 2015, 33, 2400–2415. [Google Scholar] [CrossRef] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, B.-H.; Lee, H.; Park, C.G.; Jeong, A.J.; Lee, S.-H.; Noh, K.H.; Park, J.B.; Lee, C.-G.; Paek, S.H.; Kim, H.; et al. STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model. Cells 2020, 9, 722. https://doi.org/10.3390/cells9030722
Kim B-H, Lee H, Park CG, Jeong AJ, Lee S-H, Noh KH, Park JB, Lee C-G, Paek SH, Kim H, et al. STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model. Cells. 2020; 9(3):722. https://doi.org/10.3390/cells9030722
Chicago/Turabian StyleKim, Byung-Hak, Haeri Lee, Cheol Gyu Park, Ae Jin Jeong, Song-Hee Lee, Kum Hee Noh, Jong Bae Park, Chung-Gi Lee, Sun Ha Paek, Hyunggee Kim, and et al. 2020. "STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model" Cells 9, no. 3: 722. https://doi.org/10.3390/cells9030722